Nautilus Biotechnology is wildly overvalued at about $250M on just $190K of trailing-12-month revenue, a price richer than early-stage VC. That rebuts @alc2022's case that it owns the read layer for the proteome and could return 100-1,000x. x.com 

Even an extension for SVRN's listing concerns could buy enough time for its shares to take off. Addressing the concerns outright could do the same; the overdue filing still leaves the delisting risk unresolved. x.com  x.com 

Voyager's single-molecule approach could make Nautilus the most asymmetric proteomics bet if it works. Quarterly grant revenue of about $0.2m against over $10m consumed leaves it reliant on capital; a $125m ATM risks dilution. Repeated slips make the mid-2027 launch less likely to hold; independent customer validation and a sales channel are absent. Adoption could justify billions; delay or low-price issuance could send shares below $2 again. Tempus AI remains the preferred larger holding. x.com 

Recursion Pharmaceuticals looks like a falling knife despite a compelling idea behind the company. @WessexCapital calls it a financial disaster that is perpetually raising money. A large capital raise and the resulting drop would be the signal to consider it, perhaps around $1, as a lottery-style venture bet. x.com 

Ouster, Applied Optoelectronics, Ondas, AST SpaceMobile, IREN and Oklo are statistically more likely to lose money long term if bought today. Most unprofitable retail favorites end up with horrendous charts years later, and survivorship bias is far worse among them, as the 2021 vintage shows. Big winners often come from unglamorous names like Marathon Petroleum, up over 20x in six years. Applied Optoelectronics may work on real demand, but its CEO has failed for 30 years. Keep such bets small. … Show more

Biotech's usual Q4 strength ahead of JPM season makes aggressive rallies in smaller names highly likely. ARKG is starting to break out, and PDS Biotechnology is showing multiple buy signals. If ARKG keeps running as expected, Nautilus Biotechnology, PDS Biotechnology and Quantum-Si could reasonably rally toward about $10 soon; broken chart structures would invalidate that view. x.com  x.com 

Nautilus Biotechnology could become extraordinarily important to oncology by reading intact proteoform states across cancer's redundant signaling pathways. Before-and-after tumor measurements could train AI to find the smallest effective, tumor-specific drug combination beyond mutation-guided care. It has not shown it can map every clinically relevant cancer proteoform or prescribe curative combinations. AI-biology companies must buy Nautilus now or face painfully compressed margins. x.com  x.com 

Zeta Global and Nautilus Biotechnology are two versions of the same idea, seeing deeper than anyone else: Zeta into the customer, Nautilus into the molecule. Both are aligned with something everyone wants, better information, and moved first to build the platforms that deliver it. Neither guarantees success, but both greatly raise the odds, which creates the asymmetry. Zeta is much further along in its zero-to-one journey. x.com 

Nautilus Biotechnology is entering commercialization and could become the Illumina of proteomics. Its early access program signed Baylor College of Medicine as first customer for an NIH-funded cancer project. Its tau assay with the Buck Institute quantifies up to 768 full-length tau proteoforms, beyond traditional methods, which could draw pharma demand or M&A interest as Alzheimer's drug work heats up. Its $143 million cash lasts past 2028 at $14-16 million quarterly burn, avoiding dilution. … Show more